Latest Commercialization News

Page 72 of 481
Clarity Pharmaceuticals reports robust progress in prostate cancer and neuroendocrine tumour trials alongside a strong cash position of $226.2 million, underpinning its path towards commercialisation.
Ada Torres
Ada Torres
30 Jan 2026
Southern Palladium has made significant strides in advancing its Bengwenyama platinum group metals project, completing key drilling and regulatory milestones while securing A$20 million in fresh capital to fund the next development phase.
Maxwell Dee
Maxwell Dee
30 Jan 2026
IMEXHS Limited has reported a strong finish to FY25, delivering revenue and underlying EBITDA at the top end of its guidance, driven by robust software growth and expanding recurring revenue.
Ada Torres
Ada Torres
30 Jan 2026
Cobalt Blue Holdings has enhanced the financial outlook for its Kwinana Cobalt Refinery project, secured a $5.3 million capital raise, and advanced key environmental and feedstock initiatives amid a tightening cobalt market.
Maxwell Dee
Maxwell Dee
30 Jan 2026
ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.
Ada Torres
Ada Torres
30 Jan 2026
4DMedical has secured a commercial contract with University of Chicago Medicine to deploy its CT, VQ™ lung imaging technology, marking the fifth major US academic medical centre to adopt the platform since FDA clearance.
Ada Torres
Ada Torres
30 Jan 2026
HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.
Victor Sage
Victor Sage
30 Jan 2026
IPB Petroleum is set to expand its footprint into Alaska’s National Petroleum Reserve with a major lease acquisition, supported by a recent $1.27 million capital raise. The company also plans a rebrand to Forte Energy, signalling a new chapter.
Maxwell Dee
Maxwell Dee
30 Jan 2026
4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.
Ada Torres
Ada Torres
30 Jan 2026
Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.
Ada Torres
Ada Torres
30 Jan 2026
Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.
Ada Torres
Ada Torres
30 Jan 2026
Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.
Ada Torres
Ada Torres
30 Jan 2026